Biogen (BIIB) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for Biogen (BIIB) over the last 10 years. The current PE ratio for Biogen as of February 20, 2018 is 13.18.
|Medical||Medical - Biomedical and Genetics||$60.814B||$12.274B|
|Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.|